ASX Health Stocks: Alcidion wins Aussie government contract, while Resonance seeks US FDA nod
Health & Biotech
Health & Biotech
Link copied to
The ASX 200 Health Index (XHJ) is down by 0.67% at the time of writing, compared to the broader index which is up by 0.47%.
Alcidion Group (ASX:ALC) rose nearly 8% this morning, after revealing that it was a member of a consortium awarded a contract by the Australian government to provide components of an enterprise Health IT Project.
The consortium is led by global consulting firm Leidos Australia, and involves several other digital health partners, many of them leading Australian providers.
Under the terms, Alcidion is to provide the Longitudinal Health Record to the government, via its Miya Precision product.
The Miya Precision platform will aggregate data from consortium partner solutions and other systems to establish a consolidated view of every participant health status and history.
The contract value for Alcidion is estimated to be $23.3m over six years.
Resonance says its LiverSmart application dossier has been submitted to the US FDA for a Special 510k medical device regulatory clearance.
LiverSmart is the company’s newest AI medical device that combines two existing regulatory-cleared Resonance products, FerriSmart and HepaFat-AI.
The device combines them into a single multi-parametric MRI (magnetic resonance imaging) session, avoiding the need for multiple MRI appointments for a liver scan.
Instead of obtaining individual FerriSmart and HepaFat-AI reports via separate scanner sessions, which adds to cost and inconvenience, patients could obtain both analyses at the same time in one consolidated report.
Resonance believes that LiverSmart may be eligible for two new US (Category III) Current Procedural Technology (CPT) codes recently published by the American Medical Association.
The oncology-focused company announced positive final data from its Phase II clinical study of paxalisib, a first line therapy in patients with glioblastoma.
The results confirmed the previously reported safety and efficacy profile of paxalisib.
The study recruited 30 patients with newly diagnosed glioblastoma, and unmethylated MGMT promoter status.
The patients were given 60mg of daily doses of paxalisib, and results showed a median overall survival of 15.7 months, which compares favourably to 12.7 months historically reported with temozolomide in this patient group.
Kazia expects to receive a final clinical study report in the first quarter of 2022, and intends to seek publication of these data in a peer-reviewed scientific journal thereafter.
Starpharma (ASX:SPL) +3.5%
Following this week’s registration of VIRALZEE in Vietnam, Starpharma has now signed a 5-year distribution agreement for the antiviral nasal spray in the country.
The multiple five-year agreements include a minimum commitment of at least 1 million units in the first year, with ongoing performance obligations.
VIRALEZE is an antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral activity that kills >99.9% of the Delta variant of SARS-CoV in laboratory studies.
The spray is currently registered in Europe, India, New Zealand and Vietnam, and available in certain markets online.
The giant biotech company denied any certainty in the proposed acquisition of Swiss biopharmaceutical Vifor proceeds.
The company released a statement saying: “There is no certainty that any transaction will result from CSL’s consideration of such opportunities and, if any transaction does result, when such a transaction would occur.”